基于美国国家癌症数据库的西班牙裔美国人前列腺癌差异研究
该回顾性分析纳入2004至2015年54,947例确诊前列腺癌的西班牙裔美国成人,按原籍国分组比较疾病特征与治疗。墨西哥裔初诊时疾病特征最差,古巴裔总生存最差且最常接受激素和放疗,多米尼加裔、中南美裔及原籍未指明者生存优于墨西哥裔。
要点
- 墨西哥裔初诊时中位PSA最高(7.8 ng/mL)、T3/T4期(6.7%)、M1期(8.9%)及高分级Gleason评分(24.0%)占比最高。
- 古巴裔最常接受激素治疗和放疗、最不常接受手术治疗,且总生存劣于墨西哥裔(HR=1.30,95%CI 1.16-1.44)。
- 多米尼加裔(HR=0.63,95%CI 0.53-0.75)、中南美裔(HR=0.75,95%CI 0.66-0.84)及原籍未指明者(HR=0.84,95%CI 0.79-0.91)总生存优于墨西哥裔。
核心结论
- 不同原籍国的西班牙裔美国人在前列腺癌特征、治疗选择及生存方面存在差异。
- 墨西哥裔初诊时前列腺癌特征最不理想;古巴裔总生存最差且最可能接受激素和/或放疗作为一线治疗。
- 该分析显示西班牙裔美国人群体存在显著异质性。
研究设计与样本
- 基于美国国家癌症数据库的回顾性分析,纳入2004至2015年确诊前列腺癌的54,947例西班牙裔美国成人。
- 按原籍国分组:墨西哥裔7844例(14.3%)、中南美裔4010例(7.3%)、波多黎各裔2938例(5.4%)、古巴裔2549例(4.6%)、多米尼加裔1535例(2.8%)、原籍未指明36,269例(65.7%)。
- 分类变量采用卡方检验、连续变量采用Kruskal-Wallis检验比较组间特征。
主要发现
- 墨西哥裔中位PSA为7.8 ng/mL,T3/T4期占6.7%,M1期占8.9%,高分级Gleason评分占24.0%,均为各组最高。
- 古巴裔最常接受激素治疗和放疗,最不常接受手术治疗。
- 与墨西哥裔相比,古巴裔总生存更差(HR=1.30,95%CI 1.16-1.44),波多黎各裔总生存相似(HR=1.08,95%CI 0.95-1.19)。
- 与墨西哥裔相比,多米尼加裔(HR=0.63,95%CI 0.53-0.75)、中南美裔(HR=0.75,95%CI 0.66-0.84)及原籍未指明者(HR=0.84,95%CI 0.79-0.91)总生存更好。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the differences in prostate cancer characteristics and treatment between Hispanic Americans with different countries of origin using the National Cancer Database. METHODS: We performed a retrospective analysis of 54,947 adult Hispanic Americans diagnosed with prostate cancer between 2004 and 2015. Origin was Mexican (N = 7844; 14.3%), South/Central American (N = 4010; 7.3%), Puerto Rican (N = 2938; 5.4%), Cuban (N = 2549; 4.6%), Dominican (N = 1535; 2.8%), Hispanic not specified (N = 36,269; 65.7%). Comparison between characteristics among Hispanic American sub-groups' categories was performed using chi-square and Kruskal-Wallis tests for categorical and continuous variables respectively. RESULTS: Mexicans had overall worse disease at presentation including highest median PSA (7.8 ng/mL), most prevalent T3/T4 stage (6.7%), M1 stage (8.9%), and high-grade Gleason scores (24.0%) when compared to all other Hispanic American groups. Cubans were most likely to receive hormone therapy and radiation therapy and least likely to receive surgical treatment. Compared to Mexicans, Cubans (hazards ratio [HR] = 1.30, 95% confidence interval = [1.16-1.44]) had worse overall survival, while Puerto Ricans (HR = 1.08 [0.95-1.19] had similar overall survival, and Dominicans (HR = 0.63 [0 0.53-0.75]), South/Central Americans (HR = 0.75, [0.66-0.84]) and not specified (HR = 0.84 [0.79-0.91]) had better survival. CONCLUSION: Among Hispanic Americans with different countries of origin, disparities in prostate cancer characteristics, treatment choice, and survival do exist. Mexicans had the least favorable prostate cancer characteristics at presentation. Cubans had the worst overall survival while they were also most likely to receive hormone and/or radiation as first-line treatment. Our analysis demonstrates significant heterogeneity in the Hispanic American population.
引用
- Del Pino M, Abern MR, Moreira DM, et al. Prostate Cancer Disparities in Hispanics Using the National Cancer Database. Urology. 2022. PMID: 35351485. doi:10.1016/j.urology.2022.02.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。